Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: BRT develops therapeutic products using adult stem cells. Key programs include brtxDISC (BRTX-100 for lumbar disc disorders), the ThermoStem Program (brown adipose for metabolic disorders), and a biologics-based cosmetic business. The company recently entered a five-year exclusive supply agreement with Cartessa Aesthetics, LLC.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenues | $124,100 | $95,800 |
| Net Loss | $(6,251,817) | $(12,881,971) |
| Net Loss Per Share (Basic & Diluted) | $(0.84) | $(3.39) |
| Cash and Cash Equivalents (End of Period) | $2,252,247 | $1,783,646 |
| Investments in Marketable Securities | $12,428,218 | $10,181,618 |
| Working Capital | $9,683,935 | $8,783,181 |
| Derivative Liabilities | $4,491,969 | $1,543,953 |
| Accumulated Deficit | $(152,951,151) | $(149,163,601) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 29.5% year-over-year (YoY) to $124,100, driven by $69,300 in new product sales from the Cartessa agreement, partially offset by a decline in royalty revenue.
- Reduced Net Loss: Net loss decreased significantly to $6.25 million from $12.88 million in the prior year. This improvement was primarily due to a one-time gain on exchange of warrants of $1.71 million and reduced stock-based compensation expenses.
- Operating Expenses: Total operating expenses decreased 25.5% to $6.70 million. General and Administrative (G&A) expenses dropped 37% largely due to lower stock-based compensation, while R&D expenses increased 10% due to higher lab supply and payroll costs.
- Financing Activity: The company raised approximately $7.5 million in net proceeds through a warrant exercise and issuance program, significantly bolstering liquidity compared to the prior period.
- Derivative Liabilities: The fair value of derivative liabilities increased to $4.49 million from $1.54 million, resulting in a non-cash loss of $1.87 million on the change in fair value.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash and investments are sufficient to fund operations for at least 12 months. However, the company expects to continue incurring net losses and will require additional financing to complete clinical trials and achieve profitability.
- Restatement: The financial statements for prior periods have been restated. The company notes that professional fees increased in the current period related to this restatement.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024. Material weaknesses persist, including a lack of formal policies, insufficient risk assessment, and ineffective controls over warrant accounting. Remediation efforts are underway.
- Risk Factors: Key risks include the ability to secure necessary financing, the success of clinical trials for BRTX-100, and the volatility of derivative liabilities.
Investor Verification Checklist
- Warrant Accounting: Verify the valuation assumptions (volatility, term) used for the $4.49 million derivative liability, as this significantly impacts reported net loss.
- Restatement Impact: Review the details of the financial restatement filed in the Form 10-K/A to understand the nature of prior errors and the reliability of current figures.
- Internal Control Remediation: Monitor the progress of remediation for material weaknesses in internal controls, specifically regarding warrant accounting and financial reporting policies.
- Revenue Concentration: Note that all contract service revenue and all product sales revenue are derived from single customers (SCTC and Cartessa, respectively).
- Abeyance Shares: Confirm the status of the 1,201,580 shares held in abeyance for Auctus Fund, LLC, which are fully paid but not yet issued.